- Home
- STT vs TEVA Comparison
STT vs TEVA Comparison
Compare STT & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STT | TEVA |
|---|---|---|
| Founded | 1792 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 40.5B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | STT | TEVA |
|---|---|---|
| Price | $166.35 | $40.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $199.03 | $47.17 |
| AVG Volume (30 Days) | 1.8M | ★ 5.3M |
| Earning Date | 10-14-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | 14.49 | ★ 183.45 |
| EPS | ★ 6.14 | N/A |
| Revenue | ★ $13,944,000,000.00 | N/A |
| Revenue This Year | $14.54 | N/A |
| Revenue Next Year | $5.30 | $3.39 |
| P/E Ratio | $28.33 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $104.64 | $18.83 |
| 52 Week High | $195.93 | $42.02 |
Technical Indicators
Market Signals| Indicator | STT | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 22.74 | 62.59 |
| Support Level | $164.74 | $30.41 |
| Resistance Level | $194.76 | N/A |
| Average True Range (ATR) | 3.53 | 1.06 |
| MACD | -0.57 | 0.07 |
| Stochastic Oscillator | 37.27 | 69.76 |
Price Performance
Historical ComparisonAbout STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $54 trillion in assets under custody and administration, and $5.7 trillion in assets under management, as of Dec. 31, 2025, State Street operates globally in more than 100 geographic markets and employs about 51,500 worldwide.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.